|
WO2010009190A1
|
|
Methods of treating atherosclerosis
|
|
WO2010009194A1
|
|
Methods of treating atherosclerosis
|
|
CA2716501A1
|
|
Crystal forms of 2-{2-[(cyclohexyl)methylene]hydrazino}adenosine
|
|
EP2225255A1
|
|
Crystal forms of 2-[2-(4-chlorophenyl)ethoxy]adenosine
|
|
WO2009015004A1
|
|
Crystals of (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(4-chlorophenyl)methanone
|
|
WO2008134047A1
|
|
Methods of treating hypertension
|
|
US2008242673A1
|
|
Adenosine A2A receptor antagonists
|
|
EP2081575A2
|
|
Allosteric modulators of the a1 adenosine receptor
|
|
CN101534828A
|
|
Allosteric modulators of the A1 adenosine receptor
|
|
US2008119460A1
|
|
Allosteric modulators of the A1 adenosine receptor
|
|
US2008125438A1
|
|
Allosteric modulators of the A1 adenosine receptor
|
|
WO2008057464A2
|
|
Compositions and methods for improving the bioavailability of liothyronine
|
|
CA2666925A1
|
|
Combination therapy for the treatment of pain
|
|
US2008045549A1
|
|
Adenosine A2B receptor antagonists
|
|
US2007281902A1
|
|
Adenosine A2B receptor agonists
|
|
WO2007140181A2
|
|
Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist
|
|
CA2646446A1
|
|
Pharmaceutical compositions for promoting wound healing
|
|
EP1948136A1
|
|
Compositions of stabilized ramipril in combination with another active agent
|
|
BRPI0610339A2
|
|
method for preparing recovered bovine thrombin, and method for preparing a purified bovine thrombin composition
|
|
CN101365467A
|
|
Thrombin purification
|
